NCT00194779 - Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2003

Primary Completion Date

June 30, 2010

Study Completion Date

June 30, 2011

Conditions

Estrogen Receptor-negative Breast CancerEstrogen Receptor-positive Breast CancerHER2-positive Breast CancerProgesterone Receptor-negative Breast CancerProgesterone Receptor-positive Breast CancerStage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIIA Breast Cancer

Interventions

DRUG

doxorubicin hydrochloride

Given IV

DRUG

cyclophosphamide

Given PO

DRUG

paclitaxel

Given IV

BIOLOGICAL

filgrastim

Given SC

DRUG

capecitabine

Given PO

DRUG

methotrexate

Given IV

DRUG

vinorelbine tartrate

Given IV

PROCEDURE

needle biopsy

Correlative studies

PROCEDURE

therapeutic conventional surgery

Undergo definitive breast surgery

OTHER

immunohistochemistry staining method

Correlative studies

BIOLOGICAL

trastuzumab

Given IV

DRUG

tamoxifen citrate

Given PO

DRUG

letrozole

Given PO

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER